Risk of venous thromboembolism with combined hormonal contraceptives*
| Category of woman | Risk of developing VTE in a year (per 10 000 women) |
|---|---|
| Non-pregnant non-user of CHCs | 2 |
| Woman using CHCs containing levonorgestrel, norethisterone, norgestimate | 5–7 |
| Woman using CHCs containing etonogestrel, norgestromin | 6–12 |
| Woman using CHCs containing drospirenone, gestodene, desogestrel | 9–12 |
*Adapted from the Assessment Report for Combined Hormonal Contraceptives Containing Medicinal Products.9
CHC, combined hormonal contraceptive; VTE, venous thromboembolism.